Mass General Brigham Secures $66 Million for Alzheimer’s Study

The funding supports a four-year clinical research project to test multiple drug combinations for preventing the disease.

Updated on Oct. 21, 2026 in Alzheimer’s

Mass General Brigham Secures $66 Million for Alzheimer’s Study

Live Poll

Should medical research funding prioritize preventative treatments for age-related diseases like Alzheimer's?

Mass General Brigham has secured $66 million in new funding to launch a four-year study targeting the prevention of Alzheimer’s disease. Led by Rudolph Tanzi, the project will evaluate the efficacy of five to 10 drug combinations on 300 patients who have tested positive for disease-related biomarkers.

Why it matters

This research aims to block the accumulation of harmful amyloid proteins in the brain before symptoms manifest in at-risk individuals. By testing drug combinations on human brain cells in a lab model before moving to patients, scientists hope to establish a path toward preventing the disease entirely.

The study received $41 million from federal health grants and $25 million from private philanthropy. Researchers will test potential preventative treatments on a cohort of 300 patients.

The players

Rudolph Tanzi

He is a prominent neuroscientist who heads the Henry and Allison McCance Center for Brain Health.

Mass General Brigham

This is an integrated academic healthcare system that serves as a primary site for medical research in Boston.

Acta Pharmaceuticals

This is a biotech company based in Boston that is currently pursuing its own clinical trials for experimental Alzheimer's medicine.

Advanced Research Projects Agency for Health

This is a federal agency that provides grants for high-risk, high-reward biomedical research projects.

The details

Researchers will utilize a laboratory model involving gel and human brain cells to screen potential substances. In a separate development, Boston-based Acta Pharmaceuticals has raised $24 million in seed financing to begin an independent clinical trial involving 72 participants.

1980: Rudolph Tanzi began his tenure at Massachusetts General Hospital.
2014: The research team developed an Alzheimer's in a Dish model.
2023: Biogen and Eisai received approval for the treatment Leqembi.
October 15, 2026: Acta Pharmaceuticals announced its seed financing.
October 21, 2026: Mass General Brigham announced the research funding.

Health Landscape

This research project follows a pattern set by the 2023 FDA approval of Leqembi by focusing on amyloid-targeted therapies. The work extends the current therapeutic focus by shifting from treating existing cognitive decline toward early-stage prevention.

This research could eventually provide at-risk individuals with preventative medication options that currently do not exist. Patients should monitor clinical trial registries if they are concerned about their personal risk for Alzheimer's disease.

The takeaway

Ongoing developments in drug testing are rapidly shifting the strategy for addressing neurodegenerative conditions. Early screenings and participation in clinical research remain the most critical actions for individuals looking to address potential cognitive health risks.